SG11202104365QA - Edaravone suspension for oral administration - Google Patents
Edaravone suspension for oral administrationInfo
- Publication number
- SG11202104365QA SG11202104365QA SG11202104365QA SG11202104365QA SG11202104365QA SG 11202104365Q A SG11202104365Q A SG 11202104365QA SG 11202104365Q A SG11202104365Q A SG 11202104365QA SG 11202104365Q A SG11202104365Q A SG 11202104365QA SG 11202104365Q A SG11202104365Q A SG 11202104365QA
- Authority
- SG
- Singapore
- Prior art keywords
- oral administration
- edaravone suspension
- edaravone
- suspension
- oral
- Prior art date
Links
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 title 1
- 229950009041 edaravone Drugs 0.000 title 1
- 239000000725 suspension Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018207646 | 2018-11-02 | ||
| PCT/JP2019/043013 WO2020091036A1 (en) | 2018-11-02 | 2019-11-01 | Edaravone suspension for oral administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104365QA true SG11202104365QA (en) | 2021-05-28 |
Family
ID=70463399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104365QA SG11202104365QA (en) | 2018-11-02 | 2019-11-01 | Edaravone suspension for oral administration |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US10987341B2 (en) |
| EP (2) | EP3875085B1 (en) |
| JP (2) | JP7274502B2 (en) |
| KR (1) | KR20210087490A (en) |
| CN (4) | CN117379369A (en) |
| AR (1) | AR116967A1 (en) |
| AU (1) | AU2019369843A1 (en) |
| BR (1) | BR112021008197A2 (en) |
| DK (1) | DK3875085T3 (en) |
| FI (1) | FI3875085T3 (en) |
| IL (1) | IL282773A (en) |
| MX (3) | MX2021005144A (en) |
| PH (1) | PH12021550988A1 (en) |
| PT (1) | PT3875085T (en) |
| SG (1) | SG11202104365QA (en) |
| TW (1) | TW202031256A (en) |
| WO (1) | WO2020091036A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019167178A1 (en) * | 2018-02-28 | 2019-09-06 | 田辺三菱製薬株式会社 | Analysis method of 3-methyl-1-phenyl-2-pyrazolin-5-one bulk drug, treatment for amyotrophic lateral sclerosis, inhibition of progression of amyotrophic lateral sclerosis, and method of producing drug containing 3-methyl-1-phenyl-2-pyrazolin-5-one bulk drug |
| TW202031256A (en) * | 2018-11-02 | 2020-09-01 | 日商田邊三菱製藥股份有限公司 | Edaravone suspension for oral administration |
| US11826352B2 (en) * | 2018-11-02 | 2023-11-28 | Mitsubishi Tanabe Pharma Corporation | Edaravone suspension for oral administration |
| EP3989968A4 (en) * | 2019-07-18 | 2023-07-12 | BDR Pharmaceuticals International Private Limited | Oral formulations of edaravone and method of manufacturing thereof |
| WO2022102737A1 (en) | 2020-11-12 | 2022-05-19 | 田辺三菱製薬株式会社 | Pharmaceutical composition for edaravone oral administration and method for administering same |
| JPWO2022102737A1 (en) | 2020-11-12 | 2022-05-19 | ||
| GB202103807D0 (en) | 2021-03-18 | 2021-05-05 | Johnson Matthey Plc | A crystalline salt of edaravone, processes for the preparation and use thereof |
| CN118632692A (en) | 2022-02-03 | 2024-09-10 | 田边三菱制药株式会社 | Agent for treating amyotrophic lateral sclerosis or inhibiting progression of amyotrophic lateral sclerosis |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61263917A (en) | 1985-05-20 | 1986-11-21 | Mitsubishi Yuka Yakuhin Kk | Cerebral function normalizing agent |
| JPH07121861B2 (en) | 1986-11-25 | 1995-12-25 | 三菱化学株式会社 | Stable injection containing 3-methyl-1-phenyl-2-pyrazolone-5-one |
| JPH0531523A (en) | 1991-07-26 | 1993-02-09 | Aichi Steel Works Ltd | Roll guide device for rolling mill which can measure number of revolution and clearance of roll |
| JP3402195B2 (en) * | 1997-05-14 | 2003-04-28 | 千寿製薬株式会社 | Aqueous suspension with good redispersibility |
| JPH1120463A (en) | 1997-06-30 | 1999-01-26 | Zexel Corp | Dual air conditioner for vehicle |
| US6933310B1 (en) | 2000-10-24 | 2005-08-23 | Mitsubishi Pharma Corporation | Therapeutic agent for amyotrophic lateral sclerosis (ALS) |
| JP2004091441A (en) | 2002-09-04 | 2004-03-25 | Mitsubishi Pharma Corp | Oral administration preparation containing pyrazolone derivative |
| JP4988204B2 (en) | 2004-02-09 | 2012-08-01 | 田辺三菱製薬株式会社 | A novel therapeutic agent for amyotrophic lateral sclerosis (ALS) or a disease caused by ALS |
| JP5836004B2 (en) * | 2010-08-12 | 2015-12-24 | 日新化成株式会社 | Solubilizer |
| US9642843B2 (en) | 2013-02-27 | 2017-05-09 | The Regents Of The University Of Michigan | Pharmaceutical compounds and use of same in cancer and tauopathies |
| JP6336246B2 (en) * | 2013-03-13 | 2018-06-06 | 大同化成工業株式会社 | Nanoparticulate preparation and production method thereof |
| TWI745358B (en) * | 2016-03-10 | 2021-11-11 | 日商大日本住友製藥股份有限公司 | Composition comprising fine particle and process thereof |
| CN105816423B (en) * | 2016-03-16 | 2018-07-20 | 福建天泰医药科技有限公司 | edaravone dosage form |
| IL268127B1 (en) * | 2017-01-17 | 2024-08-01 | Treeway Tw001 B V | Treatment comprising oral or gastric administration of edaravone |
| DK3570819T3 (en) * | 2017-01-17 | 2021-04-06 | Treeway Tw001 B V | Medical treatment comprising enteral administration of edaravone |
| KR20200024868A (en) * | 2017-07-06 | 2020-03-09 | 트리웨이 티더블유001 비.브이. | Use of edalabon for oral treatment of oxidative stress-mediated neurodegenerative diseases |
| TW202031256A (en) * | 2018-11-02 | 2020-09-01 | 日商田邊三菱製藥股份有限公司 | Edaravone suspension for oral administration |
| EP3989968A4 (en) * | 2019-07-18 | 2023-07-12 | BDR Pharmaceuticals International Private Limited | Oral formulations of edaravone and method of manufacturing thereof |
-
2019
- 2019-11-01 TW TW108139797A patent/TW202031256A/en unknown
- 2019-11-01 DK DK19880770.3T patent/DK3875085T3/en active
- 2019-11-01 CN CN202311552338.3A patent/CN117379369A/en active Pending
- 2019-11-01 PT PT198807703T patent/PT3875085T/en unknown
- 2019-11-01 EP EP19880770.3A patent/EP3875085B1/en active Active
- 2019-11-01 FI FIEP19880770.3T patent/FI3875085T3/en active
- 2019-11-01 AR ARP190103206A patent/AR116967A1/en unknown
- 2019-11-01 WO PCT/JP2019/043013 patent/WO2020091036A1/en active Application Filing
- 2019-11-01 KR KR1020217016462A patent/KR20210087490A/en unknown
- 2019-11-01 AU AU2019369843A patent/AU2019369843A1/en active Pending
- 2019-11-01 CN CN202311552339.8A patent/CN117379370A/en active Pending
- 2019-11-01 JP JP2020554977A patent/JP7274502B2/en active Active
- 2019-11-01 SG SG11202104365QA patent/SG11202104365QA/en unknown
- 2019-11-01 CN CN201980072370.7A patent/CN112969459B/en active Active
- 2019-11-01 MX MX2021005144A patent/MX2021005144A/en unknown
- 2019-11-01 EP EP24181935.8A patent/EP4420724A2/en active Pending
- 2019-11-01 BR BR112021008197-6A patent/BR112021008197A2/en unknown
- 2019-11-01 CN CN202311552337.9A patent/CN117398346A/en active Pending
-
2020
- 2020-05-12 US US16/872,741 patent/US10987341B2/en active Active
-
2021
- 2021-03-26 US US17/213,501 patent/US11241416B2/en active Active
- 2021-04-29 IL IL282773A patent/IL282773A/en unknown
- 2021-04-30 PH PH12021550988A patent/PH12021550988A1/en unknown
- 2021-04-30 MX MX2024000663A patent/MX2024000663A/en unknown
- 2021-04-30 MX MX2023009973A patent/MX2023009973A/en unknown
- 2021-12-23 US US17/560,493 patent/US11478450B2/en active Active
-
2022
- 2022-09-22 US US17/934,234 patent/US11957660B2/en active Active
-
2023
- 2023-05-01 JP JP2023075654A patent/JP2023087011A/en active Pending
-
2024
- 2024-03-26 US US18/616,227 patent/US20240226064A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282773A (en) | Edaravone suspension for oral administration | |
| IL276232A (en) | Pharmaceutical compounds | |
| GB2569961B (en) | Pharmaceutical | |
| GB2572126B (en) | Pharmaceutical | |
| GB201911928D0 (en) | Pharmaceutical compounds | |
| GB2572125B (en) | Pharmaceutical | |
| GB201810245D0 (en) | Pharmaceutical compounds | |
| HUP1700253A1 (en) | Solid preparations for oral administration | |
| GB201810239D0 (en) | Pharmaceutical compounds | |
| GB201819961D0 (en) | Pharmaceutical compounds | |
| GB201819960D0 (en) | Pharmaceutical compounds | |
| GB201911944D0 (en) | Pharmaceutical compounds | |
| ZA202006570B (en) | Pharmaceutical formulations | |
| GB201914910D0 (en) | Pharmaceutical compounds | |
| GB2591396B (en) | Pharmaceutical suspension for oral dosage | |
| IL291570A (en) | Pharmaceutical compounds | |
| GB201801562D0 (en) | Pharmaceutical compounds | |
| GB201800378D0 (en) | Pharmaceutical compounds | |
| GB201816369D0 (en) | Pharmaceutical compounds | |
| IL283273A (en) | Pharmaceutical methods | |
| ZA202006346B (en) | Pharmaceutical preparation | |
| GB201915932D0 (en) | Pharmaceutical compounds | |
| GB201915273D0 (en) | Pharmaceutical compounds | |
| GB201819937D0 (en) | Pharmaceutical compounds | |
| GB201815447D0 (en) | Pharmaceutical Compounds |